Two Compounds Supported by JDRF Donations Sell to Lilly and Glaxo for Staggering Sums of Money

| Oct 25, 2007

On January 6, 2007, the JDRF announced that it was giving $2 million to MacroGenics, a private biotechnology company, to fund a phase II/III clinical trial of teplizumab, a compound owned by MacroGenics. Teplizumab is an antibody engineered to disarm immune T cells once they're set to destroy islets, so it may preserve beta cell function in newly diagnosed diabetic patients.

The $2 million was awarded as part of the JDRF's "Industry Discovery and Development Partnership program," which allows the JDRF to "partner with" private, for-profit businesses that have the potential to develop medicines for type 1 diabetes.

Now, just nine months later, MacroGenics Inc. has entered into a deal with Eli Lilly to develop and commercialize teplizumab, and the payoff could be more than $1 billion. Under the agreement, Lilly will acquire the exclusive rights to teplizumab. MacroGenics will receive an up-front payment of $41 million and $3 million in other funds from Lilly. MacroGenics also may get up to $200 million in potential development milestones. If teplizumab, which was granted orphan drug status by the FDA in October 2006, makes it to market, MacroGenics also may receive up to $250 million more, as well as double-digit royalties on sales.

In August 2006, the JDRF also contributed $3.5 million to Tolerx, Inc., for a phase III trial of another antibody, known as TRX4 or otelixizumab, that might preserve beta cells from autoimmune attack. TRX4 received orphan drug status from the FDA in February 2006. Now Tolerx has signed a deal worth $760 million with GlaxoSmithKline to develop that drug. Tolerx will receive an upfront payment of $70 million and up to $155 million in future development costs of otelixizumab in type 1 diabetes. If all goes well, the firm may earn up to $350 million for approvals of otelixizumab and $175 million in sales milestones, plus royalty payments.

When contacted today, the JDRF reported that it has specific contracts with each of its many partner for-profit companies. When any drug that it has supported reaches certain milestones of development, such as outright commercialization, the JDRF then receives its investment back, and possibly more. The JDRF emphasizes, however, that the recent news about otelixizumab and teplizumab is just what it was hoping for when it gave financial support to the drugs in their early stages. It appears that as far as the JDRF is concerned, the baby drugs it nurtured have grown some feathers and are getting ready to fly. Hopefully, people with type 1 diabetes will eventually benefit.

* * *

Source: CNN Money.com; TolerRx website; the JDRF

For more information on the JDRF partnerships, see "A Pony For a Cure".

What is an Orphan Drug?

Any rare malady that affects fewer than 200,000 Americans or fewer than five people in 10,000 is called an orphan disease. The name stems from their general neglect by the pharmaceutical powers that be. Because pharma companies are not likely to spend big bucks developing a drug for so few potential buyers, the FDA has sweetened the pot for those who are willing to develop orphan drugs for orphan diseases. Such companies are rewarded with tax reductions (up to 50 percent of costs), fee waivers, and a monopoly on sales of the orphan drug for seven years post-approval.

Click Here To View Or Post Comments

Related Article

A Pony for A Cure

Feb 14, 2007


Categories: Diabetes, Diabetes, Professional Issues, Type 1 Issues


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Oct 25, 2007

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.